Know Cancer

or
forgot password

Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar.


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Adenocarcinoma, Bronchiolo-Alveolar

Thank you

Trial Information

Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar.


Inclusion Criteria:



- CBA histologically proven (or cytologically with pneumonic presentation) PS < 3
signed and written informed consent

Exclusion Criteria:

- visible tumoral lesion in bronchial fibroscopy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

16-week Disease Control Rate

Outcome Time Frame:

4-week

Safety Issue:

Yes

Principal Investigator

Jacques Cadranel

Investigator Role:

Principal Investigator

Investigator Affiliation:

APHP Hopital Tenon (Pneumologie) - Paris - France

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

IFCT-0504

NCT ID:

NCT00384826

Start Date:

September 2006

Completion Date:

July 2013

Related Keywords:

  • Adenocarcinoma, Bronchiolo-Alveolar
  • Adenocarcinoma, Bronchiolo-Alveolar
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Adenocarcinoma, Bronchiolo-Alveolar

Name

Location